SEC Comment Letter 0000000000-24-009823 to Silo Pharma, Inc. (SILO)

Silo Pharma, Inc.
Date: Aug. 28, 2024 · CIK: 0001514183 · Accession: 0000000000-24-009823

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-281692

Date

August 28, 2024

Author

Eric Weisblum

Form

UPLOAD

Company

Silo Pharma, Inc.

Letter

August 28, 2024 Eric Weisblum Chief Executive Officer Silo Pharma, Inc. 677 N. Washington Boulevard Sarasota, Florida 34236 Re:Silo Pharma, Inc. Registration Statement on Form S-1 Filed August 21, 2024 File No. 333-281692 Dear Eric Weisblum: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Richard Friedman, Esq.

Show Raw Text

August 28, 2024
Eric Weisblum
Chief Executive Officer
Silo Pharma, Inc.
677 N. Washington Boulevard
Sarasota, Florida 34236
Re:Silo Pharma, Inc.
Registration Statement on Form S-1
Filed August 21, 2024
File No. 333-281692
Dear Eric Weisblum:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Richard Friedman, Esq.

SecProbe.io